United States securities and exchange commission logo





                              August 7, 2023

       Jack K. Heilbron
       Chief Executive Officer
       Murphy Canyon Acquisition Corp.
       4995 Murphy Canyon Road, Suite 300
       San Diego, CA 92123

                                                        Re: Murphy Canyon
Acquisition Corp.
                                                            Amendment No. 2 to
Registration Statement on Form S-4
                                                            Filed July 28, 2023
                                                            File No. 333-271903

       Dear Jack K. Heilbron:

              We have reviewed your amended registration statement and have the
following
       comment. In our comment, we may ask you to provide us with information
so we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our July
20, 2023 letter.

       Amendment No. 2 to Form S-4 filed July 28, 2023

       Business of Conduit Pharmaceuticals Limited
       Our Initial Pipeline: AZD1656 and AZD5904, page 150

   1.                                                   We note your response
to our prior comment 8 and the table now included on page 150,
                                                        notably the last column
of the table. Please revise your disclosure to explain how the listed
                                                        candidates may reach
commercialization "following completion of Phase II" rather than
                                                        following the
successful completion of Phase III clinical trials.
 Jack K. Heilbron
FirstName   LastNameJack  K. Corp.
                             Heilbron
Murphy Canyon    Acquisition
Comapany
August      NameMurphy Canyon Acquisition Corp.
        7, 2023
August
Page 2 7, 2023 Page 2
FirstName LastName
       You may contact Li Xiao at 202-551-4391 or Mary Mast at 202-551-3613 if
you have
questions regarding comments on the financial statements and related matters.
Please contact
Tyler Howes at 202-551-3370 or Laura Crotty at 202-551-7614 with any other
questions.



                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:      Avital Perlman, Esq.